PulseAGGREGATOR

Feed Stories Sources Features FAQs

PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Your news command center for 10,000+ sources. Search, filter, and set alerts — then cut through the noise with bias analysis, story clustering, and blindspot detection.

Healio

healthCenter

2h ago

VEGF/Ang-2 inhibitor ‘potentially exciting development’ in diabetic macular edematranslating…

1 min readUSAHealio (SLACK Incorporated)

Sunir J. Garg, MD, FACS, FASRS, discussed findings from a proof-of-concept clinical trial comparing OLN324, a bispecific antibody targeting VEGF and Ang-2, with faricimab in patients with diabetic macular edema in this video with Healio.

Factuality

74/100

Political Bias

Center

Ownership

Healio (SLACK Incorporated)

Region

USA

Read Original ↗

VEGF/Ang-2 inhibitor ‘potentially exciting development’ in diabetic macular edema | Pulse Aggregator